PT-141, known formally as bremelanotide and marketed under the brand name Vyleesi, is a cyclic heptapeptide that began as a metabolite of Melanotan II before becoming one of the best-characterised melanocortin receptor agonists in research. Its distinction from peripheral-acting compounds is fundamental: PT-141 acts through the central nervous system rather than through vascular mechanisms, which is why it has attracted sustained interest across neuroscience, behavioural, and metabolic research. For researchers, it offers the unusual combination of an approved drug's clinical dataset and an investigational peptide's flexibility.

PT-141 is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH and a molar mass of 1025.18 g/mol. It is a non-selective agonist of the melanocortin receptor family, engaging MC1R, MC3R, MC4R, and MC5R. The receptor most relevant to its central effects is MC4R, which is expressed in the hypothalamus and limbic system and mediates arousal and appetite pathways. MC1R activation drives melanogenesis, while MC3R modulates energy balance and feeding behaviour. The peptide carries a half-life of approximately 2.7 hours, and its classification within nootropic research reflects this CNS-mediated profile rather than a peripheral one.

The most significant milestone in PT-141 research came in 2019, when the RECONNECT Phase 3 trials, enrolling 1,247 premenopausal women, demonstrated significant improvements in sexual desire scores and in the number of satisfying sexual events compared with placebo. Those results supported FDA approval of bremelanotide as Vyleesi for hypoactive sexual desire disorder, making PT-141 one of the few peptides with a regulatory approval rooted in a melanocortin mechanism.

Mechanistic reviews emphasise that MC4R activation in the hypothalamus drives arousal through distinct CNS pathways that are independent of blood flow. A 2007 review in the Journal of Sexual Medicine laid out this pharmacological rationale explicitly, contrasting bremelanotide's central mechanism with peripheral approaches and identifying MC4R as the key receptor for CNS-mediated sexual function. Unlike peripheral vasodilators, PT-141 does not require visual or physical stimulation to produce its effects in study models, a distinction that has made it a valuable probe for mapping the neurocircuitry of desire and a useful comparator for vascular-acting compounds in behavioural assays.

Beyond arousal research, PT-141 is studied for appetite suppression via MC3R and MC4R activation and for melanogenesis via MC1R. These off-target activities are consequences of its non-selectivity and are directly relevant to researchers using the peptide as a melanocortin pathway tool rather than a single-receptor probe. The same receptor promiscuity that complicates behavioural interpretation also makes PT-141 useful for studying cross-talk between melanocortin systems, such as whether appetite and arousal effects share downstream signalling through MC4R-expressing hypothalamic neurons.

In approved use, bremelanotide is administered at 1.75 mg subcutaneously as needed, with a maximum of eight doses per month per FDA labelling, and research protocols have explored a 0.75 to 2.5 mg dose range. Administration timing is typically 45 minutes before the anticipated effect, and the monthly dose ceiling is an important design consideration for repeated-measures studies, as it reflects the tolerability and blood pressure considerations documented in the clinical programme.

Safety considerations are well documented in the clinical literature. Nausea occurred in roughly 40% of trial participants, and transient blood pressure increases of about 6 mmHg systolic and 3 mmHg diastolic have been reported, which is why uncontrolled hypertension is a stated contraindication. Chronic MC1R stimulation also carries theoretical pigmentary and melanocyte considerations for long-term protocols. Investigators running repeated-dosing studies should therefore include blood pressure monitoring in their protocols, particularly in hypertensive or older subjects.

For research sourcing, PT-141 should be verified by third-party HPLC and LC-MS with purity above 99%, and because of its cyclic structure, mass spectrometry confirmation of the intact ring is particularly important. Lyophilized peptide should be stored at -20°C, with reconstituted solutions refrigerated per protocol. Researchers building a supply chain value documented batches and reliable logistics — PeptidePlaza offers worldwide shipping with discreet packaging and cryptocurrency acceptance. PT-141 is a prescription medication in approved contexts and is intended for research use only outside of those settings.

PT-141 stands out among melanocortin peptides because it has both a large clinical dataset and a precisely mapped CNS mechanism. For researchers investigating melanocortin signalling, arousal neurobiology, or the intersection of metabolic and behavioural regulation, it offers an unusually well-validated pharmacological tool with a clear path from receptor to behaviour.